Central line replacement following infection does not improve reinfection rates in pediatric pulmonary hypertension patients receiving intravenous prostanoid therapy

Figures

• 

  Fig. 1.. Organism-specific central line infections associated with trepostinil and epoprostenol treatment. Shown are the specific organisms isolated for each central line infection associated with trepostinil (left panel) and epoprostenol (right panel) treatment. The pie charts indicate the percentage of the total infections that were gram-negative (stripes) or gram positive (solid black), and each category is defined further by a list of organisms in the associated table. P values were calculated using student’s t-test to compare the mean number of GP and GN infections between the trepostinil and epoprostenol cohorts.

• 

  Fig. 2.. Central line infection rate following central line salvage compared to central line replacement. Shown are the mean infection rates (±SE) after an infection episode led to central line salvage (solid black bars) or replacement (stripes bars) for all infections (a) and by GP organisms compared with GN organisms (b). P values were calculated using student’s t-test to compare the mean infection rate of all organisms, and of GP and GN infections between the central line salvage compared to central line replacement cohorts.

• 

  Fig. 3.. Mean number of days to next infection following central line salvage compared with central line replacement. Shown are the mean number of days until the next infection (±SE) after an infection episode led to either central line salvage (solid black bars) or replacement (stripes bars) for all infections (a) and by GP organisms compared with GN organisms (b). P values were calculated using student’s t-test to compare the mean number of days until next infection of all organisms, and of GP and GN infections between the central line salvage compared to central line replacement cohorts.